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Efforts of cancer research have yielded sig-
nificant advance in our understanding on 
the complexity of cancer during the past 
several  decades.  It  is  generally  accepted 
that  cancer  development  is  a  multi-step 
and multigenic event (Hahn and Weinberg, 
2002). The hallmarks of cancer comprise 
a  series  of  genetic  and  epigenetic  gain- 
and  loss-of-functions  of  oncogenes  and 
tumor suppressor genes, respectively, that 
render cancer cells capable of unrestricted 
replication  potential,  resistance  to  pro-
apoptotic stimuli, sustained angiogenesis, 
self-sufficiency in growth signals, insensi-
tivity of growth suppressor signals, evasion 
of immune surveillance, energy metabolism 
reprogramming, and acquisition of tumor-
promoting  inflammation  (Hanahan  and 
Weinberg,  2011).  With  the  explosion  of 
knowledge on genes and molecular path-
ways that govern those cancer hallmarks, 
mechanism-based target-specific therapies 
have been developed. The rapidly emerging 
role of targeted therapies may be considered 
one of the most remarkable developments 
in the field of cancer research and therapeu-
tics over the past several decades.
Most of the target-specific drugs have 
hitherto been designed to cripple proteins 
or molecular pathways that are thought to 
be the Achilles’ heel of cancer. If the targeted 
genes or pathways are genuinely indispensa-
ble for the tumors, their inhibition should 
impede tumor propagation and progression. 
The target-specific “smart bombs” in theory 
should  discriminatingly  destroy  cancer 
cells and leave the normal cells untouched. 
The very first two drugs of this kind are 
trastuzumab/Herceptin,  a  humanized 
monoclonal  antibody  against  HER2/neu 
receptor (Baselga et al., 1998) and Imatinib, 
a BCR–ABL inhibitor (Druker et al., 2001). 
CML patients with BCR–ABL fusion pro-
tein and metastatic breast cancer patients 
with  HER2/neu  amplification  showed 
improved  response  and  survival  rates  to 
imatinib  and  trastuzumab  respectively 
(Baselga et al., 1998; Druker et al., 2001). 
Unfortunately, following initial promising 
responses, resistance is often inevitable due 
to   mechanisms, such as secondary muta-
tions of the targets (Gorre et al., 2001) and 
activation of bypass pathways (Jones and 
Buzdar, 2009). A thorough understanding 
of the resistance mechanisms will facilitate 
the development of more effective drugs.
In the recent past, targeting addictive 
oncoproteins,  such  as  receptor  tyrosine 
kinases,  has  overwhelmingly  led  drug 
development in the field of cancer target-
specific therapies. The concept of targeting 
non-oncogene addiction has been investi-
gated as an alternative anti-cancer therapy 
(Luo et al., 2009). Proteins, such as protein 
chaperone Hsp90 and proteasomes, them-
selves are not oncogenes as they have rarely 
been found mutated or amplified in tumor 
cells. Many oncogenic proteins are often 
over-produced, unfolded or misfolded due 
to their amplification, mutations, abnormal 
epigenetic, or post-translational modifica-
tions, etc., in tumor cells. As a result, cancer 
cells become addictive to Hsp90 and protea-
somal functions for survival as the latter are 
required to fold the misfolded oncoproteins, 
which otherwise will be destroyed through 
the ubiquitination-dependent proteasome 
degradation  pathways  (Whitesell  and 
Lindquist, 2005). Many Hsp90 and protea-
some inhibitors have been generated and 
showed some inhibitory effects on various 
cancer types in preclinical and clinical set-
tings (Rajkumar et al., 2005; Trepel et al., 
2010). More potent and less toxic inhibitors 
are being actively pursued. A major chal-
lenge in this field will be to identify the right 
cancer patients whose cancer cell survival is 
Hsp90- or proteasome-dependent, and to 
hit the targets right and hard in time with 
those inhibitors.
The concept of “metabolic reprogram-
ming or transformation” has emerged as 
the 7th hallmark of cancer during the past 
decade  (Hanahan  and  Weinberg,  2011). 
Many  studies  suggest  that  the  metabolic 
reprogramming is required for cancer cell 
survival and thus might be a good target for 
anti-cancer therapies (Tennant et al., 2010). 
The  observation  that  cancer  cells  show 
increased rate of glycolysis can be traced 
back to as early as 1920s (Warburg, 1923). 
Increased glycolysis under both aerobic and 
anaerobic conditions promotes diversion 
from intracellular glucose to pyruvate, ATP, 
and NADH that in turn facilitate biosynthe-
sis of nucleosides and amino acids required 
for rapid cancer cell growth and survival. 
Since most of the enzymes and proteins 
in the glycolysis pathway are ubiquitously 
expressed in the body, caution must be paid 
to selectively target tumor-specific proteins 
or enzyme isoforms in metabolic addiction-
based target-specific therapy. Glucose trans-
porter 1 (GLUT1) which is upregulated and 
promotes glucose import into the cells, and 
hexokinase which controls the first step of 
glycolysis and is upregulated by both HIF 
and Myc in many cancer types, have been 
explored as targets for anti-cancer therapies 
(Tennant et al., 2010). Challenge remains 
as  to  the  identification  of  tumor  type 
specific metabolic pathways so that bona 
fide  tumor-specific  targets  may  be  used 
to develop more efficacious and less toxic 
drugs for metabolic addiction-based target-
specific therapies.
Different molecular networks can steer 
or  buffer  overlapping  cellular  processes, 
and disruption of one network can lead 
to an acquired dependency on another. An 
example of this is synthetic lethal interac-
tion described in yeast and fruit fly, in which 
perturbation of two genes causes cell death 
(synthetic lethal) whereas perturbation of 
either gene alone exerts minimal or no effect 
on cell survival (Lucchesi, 1968; Hartman 
et al., 2001). With the discovery of RNA 
interference  (RNAi),  the  synthetic  lethal 
interaction idea has recently been adopted 
for  unbiased  screen  for  synthetic  lethal 
partners of frequently mutated but phar-
macologically non-inhibitable genes, such 
as Ras, or tumor suppressor genes (PTEN, 
P53, VHL, APC, BRCA, etc.) that are deleted 
in  tumors  and  thus  cannot  be  targeted 
(Kaelin, 2005; Kuiken and Beijersbergen, 
2010). This approach will undoubtedly lead 
to the discovery of novel drug targets and 
mechanisms of network addiction in cancer 
cells. It may also open an alternative way Frontiers in Oncology  | Cancer Molecular Targets and Therapeutics    May 2011  | Volume 1  | Article 4  |  2
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With this in mind, understanding cancer 
molecular  networks,  heterogeneity,  and 
the nature of cancer evolution will be of 
paramount importance in directing future 
target-specific  therapeutics  and  evading 
resistance.
One of the most formidable challenges 
in anti-cancer drug development in the past 
decade has been the amazing number of 
clinical drug candidates that have emerged. 
Having phase I testing of all these drugs has 
become a major hurdle and prioritization 
has  therefore  become  essential.  A  typi-
cal example is the field of tyrosine kinase 
inhibitors with inhibitors that target sev-
eral similar and partially overlapping path-
ways. Furthermore, the presence of multiple 
genetic alterations in common tumors, that 
can act as oncogenic drivers, clearly points 
to the necessity of using combinations of 
multiple drugs with multiple mechanisms 
of action, with drugs that should poten-
tially have little overlapping toxicities. The 
use of more predictive preclinical models 
to test single agents and combinations has 
been  partially  addressed  by  genetically 
engineered mouse models and orthotopic 
models, but we are still far from optimal 
prediction of efficacy in humans. Changing 
in design of phase I trials, with extension 
phases  to  assess  preliminary  activity  in 
enriched populations, the increased use of 
randomized phase II studies before embark-
ing in phase III testing and the introduc-
tion of biomarkers early in development, 
in  order  to  select  patient  populations 
more prone to respond to treatment, all 
have been taken place at a very rapid pace 
in  recent  years.  With  the  rapid  growing 
momentum of new technologies, such as 
the next-generation sequencing, proteom-
ics, and functional genomics, that allow to 
examine every molecule of a cancer cell at 
unprecedented  speed  and  cost–  effective 
manner, it is foreseeable that knowledge on 
molecular networks and heterogenic regu-
lations of cancer will be the next wave of 
explosion. Cancer target-specific therapies 
will heavily rely on the innovative ideas and 
technologies to uncover the real Archille’s 
heel of cancer. In the next several decades 
to come, we envision that combination of 
mechanism-based discretionary targeting 
of several core pathways vital for tumor 
survival may bear significant fruits in cur-
ing cancers and evading drug resistance. We 
anticipate that we will be able to find much 
suggest that CSC niche, composed of stro-
mal cells, blood vessels, and extracellular 
matrix components, plays crucial roles in 
controlling CSC self-renewal, differentia-
tion,  epithelial–mesenchymal-transition, 
invasion, and metastasis (Borovski et al., 
2011). Future CSC target therapy should 
include  targeting  and  blocking  of  CSC 
niche signaling and interaction with CSCs 
for  more  effective  eradication  of  CSCs 
(Borovski et al., 2011).
Other areas under fierce development 
in the field of target-specific therapeutics 
include exploration of innovative strategies 
to reactivate tumor suppressors and inhibit 
oncogenic transcription factor complexes. 
An example of the former is the discovery 
and  characterization  of  small  molecules 
that  reverse  the  epigenetic  silencing  of 
RASSF1A  tumor  suppressor  protein  in 
preclinical  models  (Sheikh  et  al.,  2010). 
Unlike enzymes, transcriptional factors are 
generally entailed “undruggable”. Strategies 
to  disrupt  protein–protein  interactions 
and  post-translational  modifications  of 
oncogenic transcription factor complexes 
have drawn significant attention recently 
(Gorczynski  et  al.,  2007;  Erkizan  et  al., 
2009). Last but not least, there are great 
demands for innovative ideas to develop 
novel  vehicles  carrying  drugs  specifi-
cally into the tumors and more efficiently 
through blood brain barriers.
It is disappointing to concede that resist-
ance is almost a universal rule following 
initial encouraging response in most of the 
targeted therapeutic trials to date. One of 
the potential mechanisms of resistance is 
the presence of dormant tumor cells since 
most  of  the  radio-,  chemo-,  and  target- 
therapies rely on cell division and work only 
against replicating but not quiescent cells 
(Konopleva  and  Jordan,  2011).  Another 
possibility is that multiple partially redun-
dant pathways may prevail in tumor cells, 
and when one pathway is inhibited, tumor 
cells  adopt  other  redundant  pathway(s) 
to  sustain  their  growth  (Hanahan  and 
Weinberg, 2011). The third possibility is 
that cancer cells may be constantly evolving 
and target-specific inhibition of one path-
way leads to de novo activation of another 
pathway(s) that keep(s) cancer cells alive. 
Still other mechanisms of resistance may 
be attributed to differences in pharmacog-
enomics,  metabolism,  and  intratumoral 
drug exposure among individual patients. 
to effectively treat tumors carrying those 
“non-druggable” genes. Another attractive 
aspect of synthetic lethality screen is that it 
may accelerate the search for regulators of 
target-specific inhibitor resistance in can-
cer cells. Erlotinib-treated cancer cells have 
been subjected to synthetic lethal screen 
with  a  library  containing  >600  selected 
siRNAs  against  putative  EGFR  interact-
ing proteins. Inhibition of PRKC, Aurora 
A, and Stat3 were found synthetic lethal 
with erlotinib in many erlotinib-resistant 
cell lines, indicating they may be potential 
regulators of resistance and have significant 
clinical implications in EGFR-targeted ther-
apy (Astsaturov et al., 2010). The advance-
ment of synthetic lethal screen has fueled 
the expectation toward new discoveries of 
novel biomarkers, targets, and molecular 
pathways for cancer diagnosis and therapy. 
To meet these expectations, in the years to 
come, we wish to see the improvement of 
not only RNAi technologies but also high-
throughput target validations to eliminate 
false positive discoveries.
Increasing evidence suggests that cancer 
stem cells (CSCs) are more resistant than 
other  cells  to  conventional  radiotherapy, 
chemotherapy  and  most  of  the  target-
specific therapies, though many aspects of 
CSC hypothesis remain speculative and are 
still evolving (Zhou et al., 2009). Potential 
mechanisms of the resistance can be attrib-
uted to the observation that CSCs are in 
quiescent  state  (Konopleva  and  Jordan, 
2011), resistant to DNA damage and express 
high levels of ABC drug pumps and anti-
apoptotic proteins (Zhou et al., 2009). CSCs 
that have not been eradicated can lead to 
recurrence of cancer later. Thus, regimens 
or  drugs  that  eliminate  CSCs  independ-
ent of cell cycle status may be an attrac-
tive strategy in drug development, such as 
targeting gene products and pathways, for 
example, the Hedgehog, Notch, and Wnt 
pathways among others that are activated in 
CSCs (Konopleva and Jordan, 2011). Based 
on data derived from a mouse model of 
human acute myeloid leukemia stem cells, 
it  has  been  proposed  that  induction  of 
leukemia stem cell cycle entry before treat-
ment with conventional chemotherapy may 
be feasible (Saito et al., 2010). Elucidation 
of the molecular mechanisms underlying 
the maintenance of CSC quiescence will 
undoubtedly facilitate the future CSC tar-
get therapies. Increasing bodies of evidence www.frontiersin.org  May 2011  | Volume 1  | Article 4  |  3
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better cancer specific biomarkers for early 
diagnosis and prognostic prediction, and 
to treat each patient based on his/her own 
tumor-specific molecular identities.
This journal is open to contributions in 
the field discovery of cancer target-specific 
treatments, some of which have been briefly 
described  above.  The  journal  will  be  an 
open forum for the publication of novel 
strategies for cancer treatment and novel 
technologies to identify and characterize 
potential new targets.
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